Related references
Note: Only part of the references are listed.Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody
C. Wiebe et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization
S. Amur et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Noninferiority Trials Is a New Treatment Almost as Effective as Another?
Amy H. Kaji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Reproducibility in Science Improving the Standard for Basic and Preclinical Research
C. Glenn Begley et al.
CIRCULATION RESEARCH (2015)
Pharmaceutical R&D Performance by Firm Size: Approval Success Rates and Economic Returns
Joseph A. DiMasi
AMERICAN JOURNAL OF THERAPEUTICS (2014)
Potential strategies for increasing drug-discovery productivity
John G. Cumming et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
The Calculus of Cures
Robert Kocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Six red flags for suspect work
C. Glenn Begley
NATURE (2013)
Drug discovery in pharmaceutical industry: productivity challenges and trends
Ish Khanna
DRUG DISCOVERY TODAY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Raise standards for preclinical cancer research
C. Glenn Begley et al.
NATURE (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Drug discovery management, small is still beautiful: Why a number of companies get it wrong
Lars J. S. Knutsen
DRUG DISCOVERY TODAY (2011)
Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
Francesco Trotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Belatacept
Flavio Vincenti et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?
Dimitrios T. Boumpas et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Driving personalized medicine: capturing maximum net present value and optimal return on investment
Mollie Roth et al.
PERSONALIZED MEDICINE (2010)
Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
David T. Teachey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Survival on dialysis post-kidney transplant failure: Results from the scientific registry of transplant recipients
Panduranga S. Rao et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Biomarkers and surrogate endpoints in renal transplantation:: Present status and considerations for clinical trial design
PA Lachenbruch et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Surrogate markers for long-term renal allograft survival
S Hariharan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
VMR Heydendael et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical trials, immunosuppression and renal transplantation: new trends in design and analysis
P Landais et al.
PEDIATRIC NEPHROLOGY (2002)
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
BD Kahan
LANCET (2000)
Share Paper
